期刊
CURRENT PHARMACEUTICAL DESIGN
卷 25, 期 10, 页码 1105-1114出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612825666190506122228
关键词
RAS mutation; KRAS; cancer; inhibitor; targeted drug; signal pathway
资金
- National Science and Technology Major Project of the Ministry of Science and Technology of China [2016ZX09101031]
- China Pharmaceutical University Double First-Class Construction Technology Innovation Team Project [CPU2018GY23]
RAS (H-ras, K-ras, and N-ras), as the second largest mutated gene driver in various human cancers, has long been a vital research target for cancer. Its function is to transform the extracellular environment into a cascade of intracellular signal transduction. RAS mutant protein regulates tumor cell proliferation, apoptosis, metabolism and angiogenesis through downstream MAPK, PI3K and other signaling pathways. In KRAS or other RAS-driven cancers, current treatments include direct inhibitors and upstream/downstream signaling pathway inhibitors. However, the research on these inhibitors has been largely restricted due to their escape inhibition and DOI : off-target toxicity. In this paper, we started with the role of normal and mutant RAS genes in cancer, elucidated the relevant RAS regulating pathways, and highlighted the important research advancements in RAS inhibitor research. We concluded that for the crosstalk between RAS pathways, the effect of single regulation may be limited, and the multi-target drug combined compensation mechanism is becoming a research hotspot.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据